Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma

Itano, Takuto; Huang, Rongsheng; Ozaki, Toshifumi; Nakata, Eiji; Fujimura, Atsushi

doi:10.1038/s41392-025-02548-6

Permalink : https://ousar.lib.okayama-u.ac.jp/70002

ID	70002
FullText URL	fulltext.pdf 1.09 MB
Author	Itano, Takuto Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Huang, Rongsheng Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Ozaki, Toshifumi Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Kaken ID publons researchmap Nakata, Eiji Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID Fujimura, Atsushi Department of Cellular Physiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences ORCID Kaken ID researchmap
Published Date	2026-01-22
Publication Title	Signal Transduction and Targeted Therapy
Volume	volume11
Issue	issue1
Publisher	Springer Science and Business Media LLC
Start Page	26
ISSN	2059-3635
Content Type	Journal Article
language	English
OAI-PMH Set	岡山大学
Copyright Holders	© The Author(s) 2026
File Version	publisher
PubMed ID	41565624
DOI	10.1038/s41392-025-02548-6
Related Url	isVersionOf https://doi.org/10.1038/s41392-025-02548-6
License	http://creativecommons.org/licenses/by/4.0/
Citation	Itano, T., Huang, R., Ozaki, T. et al. Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma. Sig Transduct Target Ther 11, 26 (2026). https://doi.org/10.1038/s41392-025-02548-6
助成情報	23K06676: 乳癌進展におけるメカノ応答性翻訳センサーの分子機構の解明と抗癌剤開発基盤の創成 ( 文部科学省 / Ministry of Education ) 23K08678: 脂質代謝による翻訳制御を標的とした横紋筋肉腫の革新的治療法の開発 ( 文部科学省 / Ministry of Education ) 19cm0106143: tRNAエピトランスクリプトーム創薬で実現するがん幹細胞標的型抗がん剤の開発 ( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development ) 22cm0106179: 次世代抗がん剤の創成を目指したtRNAエピトランスクリプトーム阻害剤の開発 ( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development ) ( 公益財団法人内藤記念科学振興財団 / Naito Foundation )